World's Best Scientists 2026 revealed!
Axel Heidenreich

Axel Heidenreich

D-Index & Metrics

Medicine

D-Index
92
Citations
45259
World Ranking
11099
National Ranking
601

Axel Heidenreich publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Axel Heidenreich sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,180 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Axel Heidenreich D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Axel Heidenreich sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Axel Heidenreich is affiliated with the University of Cologne in Germany and has contributed extensively to the field of medicine, with a particular focus on pulmonary and respiratory medicine, surgery, rheumatology, molecular biology, and oncology. Their research portfolio includes significant work on prostate cancer treatment and research, prostate cancer diagnosis and treatment, testicular diseases and treatments, bladder and urothelial cancer treatments, urologic and reproductive health conditions, sarcoma diagnosis and treatment, and genital health and disease.

The scientist has published numerous papers in notable venues, including:

  • Journal of Clinical Oncology
  • The Journal of Urology
  • European Urology
  • European Urology Open Science
  • British Journal of Urology

Frequent coauthors associated with Axel Heidenreich's work include David Pfister, Pia Paffenholz, Tim Nestler, Alberto Briganti, and Peter Albers.

Selected recent publications include:

  • "Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up," 2020, Annals of Oncology
  • "Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration," 2020, Journal of Clinical Oncology
  • "Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019," 2020, European Urology
  • "Rucaparib or Physician's Choice in Metastatic Prostate Cancer," 2023, New England Journal of Medicine
  • "Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium," 2021, Journal of Clinical Oncology

Axel Heidenreich's research has primarily focused on clinical and translational aspects of urologic cancers, with a strong emphasis on prostate and testicular cancers. The scope of their research also reaches into cancer therapeutics and guidelines, reflecting involvement in shaping clinical practice and treatment protocols.

The main fields of study attributed to this scientist are medicine and oncology, with their work bridging molecular biology and surgical interventions. Their body of research spans both diagnosis and treatment approaches, addressing complex urologic and reproductive health challenges.

Best Publications

  • EAU guidelines on prostate cancer

    Axel Heidenreich;Gunnar Aus;Michel Bolla;Steven Joniau

  • EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013

    Axel Heidenreich;Patrick J. Bastian;Joaquim Bellmunt;Michel Bolla

  • EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

    Axel Heidenreich;Joaquim Bellmunt;Michel Bolla;Steven Joniau

  • EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer ☆

    Nicolas Mottet;Joaquim Bellmunt;Michel Bolla;Steven Joniau

  • 前立腺癌のEAUガイドライン。パート1:臨床的限局性疾患のスクリーニング,診断および治療

    A Heidenreich;J Bellmunt;M Bolla;S Joniau

  • European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I

    Susanne Krege;Jörg Beyer;Rainer Souchon;Peter Albers

  • Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.: Annals of oncology : official journal of the European Society for Medical Oncology

    C. Parker;E. Castro;K. Fizazi;A. Heidenreich

  • Guidelines on Prostate Cancer

    A. Heidenreich;J. Bellmunt;M. Bolla;S. Joniau

  • European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

    H. J. Schmoll;R. Souchon;S. Krege;P. Albers

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • Pelvic Lymph Node Dissection in Prostate Cancer

    Alberto Briganti;Michael L. Blute;James H. Eastham;Markus Graefen

  • Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.

    Wassim Abida;Akash Patnaik;David Campbell;Jeremy Shapiro

  • Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    C. Parker;S. Gillessen;A. Heidenreich;A. Horwich

  • ICUD-EAU international consultation on bladder cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder

    Georgios Gakis;Jason Efstathiou;Seth P. Lerner;Michael S. Cookson

  • Anatomical Extent of Pelvic Lymphadenectomy in Patients Undergoing Radical Prostatectomy

    Axel Heidenreich;Carsten H. Ohlmann;Sergej Polyakov

  • Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group

    Peter Albers;Roswitha Siener;Susanne Krege;Hans-Uwe Schmelz

  • Risk Factors for Relapse in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: Results of the German Testicular Cancer Study Group Trial

    Peter Albers;Roswitha Siener;Sabine Kliesch;Lothar Weissbach

  • Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Matthew Smith;Chris Parker;Fred Saad;Kurt Miller

  • Guía de la EAU sobre el cáncer de próstata: Parte II: tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración

    N. Mottet;Joaquim Bellmunt;M. Bolla;S. Joniau

  • EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer - Guía de la EAU sobre el cáncer de próstata. Parte II: tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración

    N. Mottet;J. Bellmunt;M. Bolla;S. Joniau

Frequent Co-Authors

David G. Pfister
David G. Pfister Memorial Sloan Kettering Cancer Center
Peter Albers
Peter Albers Heinrich Heine University Düsseldorf
Silke Gillessen
Silke Gillessen Universita della Svizzera Italiana
Alberto Briganti
Alberto Briganti Vita-Salute San Raffaele University
Fred Saad
Fred Saad University of Montreal
Steven Joniau
Steven Joniau KU Leuven
Shahrokh F. Shariat
Shahrokh F. Shariat Medical University of Vienna
Francesco Montorsi
Francesco Montorsi Vita-Salute San Raffaele University
Kurt Miller
Kurt Miller Charité - University Medicine Berlin
Karim Fizazi
Karim Fizazi University of Paris-Saclay

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA opens diverse online education and advancement opportunities. While medical school remains the cornerstone for physicians, many students explore related pathways such as healthcare administration, nursing, and pharmacy for flexibility and impactful roles.

For those interested in management and leadership, exploring the cheapest mha programs online and the most affordable mha programs is a great way to discover cost-effective ways to earn a Master’s in Healthcare Administration (MHA). These programs prepare graduates for leadership roles in hospitals, clinics, and public health organizations.

Nurses hoping to advance their clinical expertise can benefit from a 1 year dnp program online, helping them fast-track their careers in advanced practice, education, or leadership.

Meanwhile, future pharmacists have options to compare online pharmacy school cost, making it easier to enter this rewarding healthcare field affordably.

By considering these related degrees, students can tailor their education to align with their career goals, timelines, and budgets without compromising on quality.

Best Scientists Citing Axel Heidenreich

Trending Scientists

Recently Published Articles